IRVINE, Calif.--(BUSINESS WIRE)--A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy.
In addition, the percentage of DTM patients who reported an MS relapse decreased by more than a third at the end of the program. These findings provide important insights into the benefits that DTM programs provide in helping patients better manage their health, while also yielding potential cost savings.
The study, published today in the American Journal of Managed Care, was conducted by Prescription Solutions, a leading pharmacy benefits management organization and a UnitedHealth Group company.
Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: http://www.msviewsandnews.org . - Thank you